New drug combo shows promise in head and neck cancer trial

NCT ID NCT02308072

Completed Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety of adding olaparib to standard chemotherapy and radiation for people with advanced head and neck cancer. Sixteen patients took part to find the best dose and see how well they tolerated the combination. The goal was to control the disease, not cure it, and patients were monitored closely for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Locations

Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom
University College London Hospitals NHS Foundation Trust

London, United Kingdom
Velindre Cancer Centre

Wales, CF14 2TL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.